niacinamide has been researched along with Lymphoma, Large B-Cell, Diffuse in 5 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Lymphoma, Large B-Cell, Diffuse: Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yin, MX | 1 |
| Su, QN | 1 |
| Song, X | 1 |
| Zhang, JX | 1 |
| Greenwald, DR | 1 |
| Li, H | 1 |
| Luger, SM | 1 |
| Go, RS | 1 |
| King, D | 1 |
| Patel, T | 1 |
| Gascoyne, RD | 1 |
| Kolesar, J | 1 |
| Kahl, BS | 1 |
| Horning, S | 1 |
| Amengual, JE | 1 |
| Clark-Garvey, S | 1 |
| Kalac, M | 1 |
| Scotto, L | 1 |
| Marchi, E | 1 |
| Neylon, E | 1 |
| Johannet, P | 1 |
| Wei, Y | 1 |
| Zain, J | 1 |
| O'Connor, OA | 1 |
| Nguyen, TK | 1 |
| Jordan, N | 1 |
| Friedberg, J | 1 |
| Fisher, RI | 1 |
| Dent, P | 1 |
| Grant, S | 1 |
| Al-Katib, A | 1 |
| Arnold, AA | 1 |
| Aboukameel, A | 1 |
| Sosin, A | 1 |
| Smith, P | 1 |
| Mohamed, AN | 1 |
| Beck, FW | 1 |
| Mohammad, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Vorinostat in Combination With Niacinamide, and Etoposide for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies[NCT00691210] | Phase 1 | 40 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The highest number of cycles received by an individual participant in the treatment groups. Each cycle was 21 days long. (NCT00691210)
Timeframe: up to 45 weeks
| Intervention | cycles (Number) |
|---|---|
| Vorinostat (SAHA) and Niacinamide: Level 1 | 9 |
| Vorinostat (SAHA) and Niacinamide: Level 2 | 12 |
| Vorinostat (SAHA) and Niacinamide: Level 3 | 15 |
| Vorinostat (SAHA) and Niacinamide: Level 4 | 10 |
| Vorinostat (SAHA) and Niacinamide: Level 5 | 14 |
| Vorinostat, Niacinamide and Etoposide: Level 1 | 3 |
| Vorinostat, Niacinamide and Etoposide: Level 2 | 4 |
(NCT00691210)
Timeframe: 3 years
| Intervention | mg/kg (Number) |
|---|---|
| Vorinostat (SAHA) and Niacinamide: Level 1-5 | 100 |
2 trials available for niacinamide and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma, Large B-Cell, Diffu | 2013 |
Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma.
Topics: Acetylation; Adult; Aged; Animals; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Eva | 2013 |
3 other studies available for niacinamide and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
[Based on CT radiomics model for predicting the response to first-line chemotherapy of diffuse large B-cell lymphoma].
Topics: Algorithms; Humans; Lymphoma, Large B-Cell, Diffuse; Niacinamide; Retrospective Studies; Tomography, | 2023 |
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Blotting, | 2010 |
I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.
Topics: Animals; Antitussive Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cyclophosph | 2010 |